Famitinib enhances the antitumor effect of radioimmunotherapy in murine lung cancer

BACKGROUND: Combining antiangiogenic therapy with radioimmunotherapy is believed to further improve antitumor efficacy, but there is still a lack of evidence to support this. This study aimed to investigate the role of the tumor vascular‐targeted agent famitinib with a combination of radiotherapy an...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuan, Meng, Zhai, Yirui, Men, Yu, Zhao, Maoyuan, Sun, Xin, Ma, Zeliang, Yang, Xu, Sun, Shuang, Bao, Yongxing, Liu, Yunsong, Hui, Zhouguang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9715775/
https://www.ncbi.nlm.nih.gov/pubmed/36281217
http://dx.doi.org/10.1111/1759-7714.14689

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9715775/
https://www.ncbi.nlm.nih.gov/pubmed/36281217
http://dx.doi.org/10.1111/1759-7714.14689

Ejemplares similares